Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

INmune Bio

  • RJ Tesi, INmune Bio

INmune Bio, the innate immunology company is proud to announce that it is now a publicly traded company (NASDAQ: INMB) and will be expanding its development programs. INMB is an immunology company that is focused on cancer with two programs in the clinic. INB03 targets myeloid derived suppressor cells (MDSC)., the cells known to cause resistance to immune checkpoint inhibitors (CPI). Combination of INB03 to inhibit MDSC should reverse resistance to CPI in an important group of patients who have failed CPI monotherapy. INKmune, a NK focused development program, has been given the green light by the MHRA to start clinical trials in women with relapsed/refractory ovarian cancer. INKmune is a biologic that prime the inert NK cells of the cancer patient to attack and kill their cancer. INMB is positioning INKmune to eliminate residual disease, the cancer that causes relapse and ultimately death in patients with cancer. INMB just completed an IPO to fund these programs into Phase II.

  • Date:Monday, February 11
  • Time:9:15 AM - 9:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23491
  • Goal for Presentation:Introduce INMB, the public company and announce new programs
  • Company Website:www.inmunebio.com
  • Company HQ City:La Jolla
  • Company HQ State:California
  • Company HQ Country:United States
  • Market Cap:<$100M
  • Ticker:INMB
  • Exchange:NASDAQ
  • CEO/Top Company Official:RJ Tesi MD
  • Year Founded:2015
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development:INB03 and INKmune
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
  • Additional Information/Comments:We are seeking three types of partners. The first is a company with an immune checkpoint inhibitor (CPI) that is interested in solving the problem of CPI resistance. INB03 targets MDSC, a cell that can be measured in tumor tissue or blood that predicts CPI resistance. We plan a biomarker directed Phase II trial in patients who have failed monotherapy with CPI with elevated MDSC in their blood. Patients will receive combination therapy with a INB03 and a CPI. We are looking for a partner to provide the CPI for this trial. We are also looking for partners for the INKmune program and for the programs to be announced at the meeting.
Speakers
RJ Tesi
INmune Bio
Back